Accumulation of Iodized Oil Within the Non-Neoplastic Liver Adjacent to Hepatocellular Carcinoma via the Drainage Routes of the Tumor After Transcatheter Arterial Embolization

Terayama, Noboru; Matsui, Osamu; Gabata, Toshifumi; Kobayashi, Satoshi; Sanada, Junichiro; Ueda, Kazuhiko; Kadoya, Masumi; Kawamori, Yasuhiro

doi:10.1007/s00270-001-0070-2

Cited by 54 publications

(40 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lipiodol is also carried to non-cancerous parenchyma surrounding the tumor via accompanying the portal veins through the peribiliary arterial plexus and/or peri-tumoral portal vessels drained through the blood sinusoid of the tumor. Consequently, higher incidence of complete necrosis is speculated to occur which is confirmed by CT and pathological examination (16,42). It is presumed that calibrated beads such as drug-eluting beads (DEBs) and EmboSpherew available in Western countries do not show the similar phenomenon as seen in lipiodol.…”

Section: Lipiodolmentioning

confidence: 90%

Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective

Takayasu

2012

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Transcatheter arterial chemoembolization has been performed worldwide for patients with unresectable hepatocellular carcinoma for three decades. After long controversy, survival benefit was revealed by two randomized controlled trials. In Japan, chemoembolization accounted for initial treatment of 32% of patients and 58% for recurrent foci. The indications of chemoembolization are various: they are multinodular tumors in the Barcelona Clinic Liver Cancer staging system and two or three tumors .3 cm or four or more tumors in the Japanese guidelines, and both indications fulfill the Child-Pugh Class A/B or liver damage A/B and exclusion of vascular invasion or extrahepatic spread. Recently, both guidelines were identified to have almost similar content. The 4966 patients stratified to chemoembolization recommended by the Japanese guidelines showed that 3-year survival of patients with two or three tumors .3 cm or four or more tumors was 55 and 46% in Child-Pugh A, respectively, and 30 and 22% in Class B, respectively. These results would help in comparing the outcome of chemoembolization in the different backgrounds of the East and West. The modified Response Evaluation Criteria in Solid Tumor guideline is now proposed to cover the deficiency of Response Evaluation Criteria in Solid Tumor to evaluate the response to chemoembolization. Recently, chemoembolization with drug-eluting beads and radioembolization with yttrium-90 microspheres have been introduced, and each of them showed similar tumor response and median survival compared with conventional chemoembolization. Moreover, the combination of chemoembolization and molecular targeted agent is now ongoing to evaluate the synergistic effect.

show abstract

Section: Lipiodolmentioning

confidence: 90%

Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective

Takayasu

2012

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…[7][8][9][10][11][12] The present study was designed to assess a diagnosis based only upon the radiological findings and to construct a scoring system for more precise preoperative prediction of microinvasion of the portal vein.…”

Section: Introductionmentioning

confidence: 99%

Accuracy of preoperative prediction of microinvasion of portal vein in hepatocellular carcinoma using superparamagnetic iron oxide-enhanced magnetic resonance imaging and computed tomography during hepatic angiography

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Continuous infusion of 5-FU may enhance the antitumor effect in cisplatin-lipiodol plus 5-FU therapy compared with other HAIC regimens. The antitumor effect has been reported to be more potent with anticancer agents in lipiodol suspension than with anticancer agents alone, such as sorafenib (42).…”

Section: Discussionmentioning

confidence: 99%

Clinical effects and safety of intra‑arterial infusion therapy of cisplatin suspension in lipiodol combined with 5‑fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra‑hepatic spread: A prospective cohort study

Nakano

Nishizaki

Nagamatsu³

et al. 2017

mol clin onc

View full text Add to dashboard Cite

Abstract. Although sorafenib and hepatic arterial infusion chemotherapy (HAIC) have been proven to improve prognosis in hepatocellular carcinoma (HCC) patients with macroscopic vascular invasion (MVI), the most appropriate approach remains unclear. The present multicenter, non-randomized, prospective cohort study aimed to compare the efficacy and safety of HAIC and sorafenib in patients with advanced HCC and MVI, without extra-hepatic spread (EHS) and Child-Pugh class A disease. The present study was performed between April 2008 and March 2014, and 64 HCC patients with MVI, without EHS and Child-Pugh class A disease were registered. Of these patients, 44 were treated with HAIC and 20 with sorafenib. HAIC involved cisplatin (50 mg fine powder in 5-10 ml lipiodol) and a continuous infusion of 5-fluorouracil (FU) (1,500 mg/5 days), which is referred to as new 5-FU and cisplatin therapy (NFP). The primary outcome was progression-free survival, and the secondary outcome was overall survival (OS). Clinical factors influencing OS and the therapeutic effect were identified using univariate and multivariate analyses. There were no differences in clinical factors between the two groups. The median progression-free survival was 5.1 and 9.5 months in the sorafenib and NFP groups, respectively (P=0.001). The complete response (CR) or partial response (PR) rates were 10 and 71% in the sorafenib and NFP groups, respectively (P<0.001). The median OS in the sorafenib and NFP groups was 13.2 and 30.4 months, respectively (P=0.013). Multivariate analysis revealed that the independent predictors of survival were Child-Pugh score (5, P=0.022, 95% CI,, grade of portal vein invasion (brunch, P=0.009, 95% CI, 0.220-0.752), and therapeutic effect (CR or PR, P<0.001, 95% CI, 0.220-0.752), and the independent predictor of therapeutic effect was therapeutic regimen (NFP, P<0.001, 95% CI,. NFP should be the first choice for patients with advanced HCC and MVI, without EHS and Child-Pugh A disease.

show abstract

Accumulation of Iodized Oil Within the Non-Neoplastic Liver Adjacent to Hepatocellular Carcinoma via the Drainage Routes of the Tumor After Transcatheter Arterial Embolization

Abstract: The drainage of blood from the HCC was considered to be a possible mechanism of the accumulation of Lipiodol in the nontumorous liver adjacent to the HCC.

Cited by 54 publications

References 23 publications

Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective

Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective

Accuracy of preoperative prediction of microinvasion of portal vein in hepatocellular carcinoma using superparamagnetic iron oxide-enhanced magnetic resonance imaging and computed tomography during hepatic angiography

Clinical effects and safety of intra‑arterial infusion therapy of cisplatin suspension in lipiodol combined with 5‑fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra‑hepatic spread: A prospective cohort study

Contact Info

Product

Resources

About